{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:28:42Z","timestamp":1784172522760,"version":"3.55.0"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vision"],"abstract":"<jats:p>This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times\/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 \u00b1 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 \u00b1 2.2 (1.5\u20139.0) months, and the follow-up period was 44.9 \u00b1 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p &lt; 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.<\/jats:p>","DOI":"10.3390\/vision5030034","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:35:22Z","timestamp":1625438122000},"page":"34","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-6741","authenticated-orcid":false,"given":"Ronald M.","family":"S\u00e1nchez-\u00c1vila","sequence":"first","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"},{"name":"Biotechnology Institute (BTI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmar","family":"Uribe-Badillo","sequence":"additional","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"},{"name":"University of San Mart\u00edn de Porres, 15011 Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez-Vega Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-1698","authenticated-orcid":false,"given":"Francisco","family":"Muruzabal","sequence":"additional","affiliation":[{"name":"Biotechnology Institute (BTI), 01007 Vitoria, Spain"},{"name":"Biotechnology Institute (BTI), University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-879X","authenticated-orcid":false,"given":"Borja","family":"de la Sen-Corcuera","sequence":"additional","affiliation":[{"name":"Biotechnology Institute (BTI), 01007 Vitoria, Spain"},{"name":"Biotechnology Institute (BTI), University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Baamonde","sequence":"additional","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-3762","authenticated-orcid":false,"given":"Luis M.","family":"Quir\u00f3s","sequence":"additional","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"},{"name":"Department of Functional Biology, University of Oviedo, 33006 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Anitua","sequence":"additional","affiliation":[{"name":"Biotechnology Institute (BTI), 01007 Vitoria, Spain"},{"name":"Biotechnology Institute (BTI), University Institute for Regenerative Medicine and Oral Implantology (UIRMI), 01007 Vitoria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-3754","authenticated-orcid":false,"given":"Jes\u00fas","family":"Merayo-Lloves","sequence":"additional","affiliation":[{"name":"Fern\u00e1ndez-Vega University Institute, Ophthalmology Research Foundation, University of Oviedo, 33071 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000439280","article-title":"Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders","volume":"55","author":"Sanchez","year":"2016","journal-title":"Ophthalmic Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/13543784.2019.1677605","article-title":"Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers","volume":"28","author":"Daruich","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00417-014-2708-1","article-title":"Simultaneous study of matrix metalloproteinases, proinflammatory cytokines, and soluble cytokine receptors in the tears of noninfectious corneal ulcer patients","volume":"252","author":"Sakimoto","year":"2014","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/S0004-27492008000700017","article-title":"Rationale for anti-inflammatory therapy in dry eye syndrome","volume":"71","author":"Pflugfelder","year":"2008","journal-title":"Arq. Bras. Oftalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Ophthalmology and Eye Diseases Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmol. Eye Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bernabei, F., Roda, M., Buzzi, M., Pellegrini, M., Giannaccare, G., and Versura, P. (2019). Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091478"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/02713683.2015.1104362","article-title":"Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases","volume":"41","author":"Anitua","year":"2016","journal-title":"Curr. Eye Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.exer.2013.07.007","article-title":"Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery","volume":"115","author":"Anitua","year":"2013","journal-title":"Exp. Eye Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2013.12.005","article-title":"Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop","volume":"119","author":"Anitua","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II Report Executive Summary","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1542-0124(12)70050-2","article-title":"Science and strategy for preventing and managing corneal ulceration","volume":"5","author":"Tuli","year":"2007","journal-title":"Ocul. Surf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1542-0124(12)70158-1","article-title":"New insights into the diagnosis and treatment of neurotrophic keratopathy","volume":"3","author":"Goins","year":"2005","journal-title":"Ocul. Surf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pan, Q., Angelina, A., Marrone, M., Stark, W.J., and Akpek, E.K. (2017). Autologous serum eye drops for dry eye [Systematic Review]. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD009327.pub3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2015.01.029","article-title":"Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia","volume":"202","author":"Anitua","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2230.2011.04303.x","article-title":"Antibacterial effect of plasma rich in growth factors (PRGF\u00ae- Endoret\u00ae) against Staphylococcus aureus and Staphylococcus epidermidis strains","volume":"37","author":"Anitua","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/ICO.0000000000000489","article-title":"Preservation of Biological Activity of Plasma and Platelet-Derived Eye Drops After Their Different Time and Temperature Conditions of Storage","volume":"34","author":"Anitua","year":"2015","journal-title":"Cornea"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/ICO.0b013e31829f7088","article-title":"Biological Stability of Plasma Rich in Growth Factors Eye Drops After Storage of 3 Months","volume":"32","author":"Anitua","year":"2013","journal-title":"Cornea"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jor.20423","article-title":"The Effect of a Subject-Specific Amount of Lateral Wedge on Knee","volume":"25","author":"Butler","year":"2007","journal-title":"J. Orthop. Res. Sept."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8181","DOI":"10.1167\/iovs.12-10476","article-title":"Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers","volume":"53","author":"Aifa","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","first-page":"457","article-title":"The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20)-A biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage","volume":"29","author":"Cejkova","year":"2014","journal-title":"Histol. Histopathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.oftal.2015.04.006","article-title":"Efectos de nuevos agentes regenerativos biomim\u00e9ticos sobre la cicatrizaci\u00f3n corneal en un modelo experimental de \u00falceras posquir\u00fargicas","volume":"90","author":"Alcalde","year":"2015","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_23","first-page":"1193","article-title":"Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops","volume":"38","author":"Riestra","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.arthro.2013.07.264","article-title":"Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A randomized controlled trial","volume":"29","author":"Vaquerizo","year":"2013","journal-title":"Arthrosc. J. Arthrosc. Relat. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/bjo.29.7.361","article-title":"The use of insulin in the treatment of corneal ulcers","volume":"29","author":"Aynsley","year":"1945","journal-title":"Br. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.oftal.2018.06.003","article-title":"Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma","volume":"94","author":"Galvis","year":"2019","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/bjo.2007.130013","article-title":"Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy","volume":"92","author":"Yamada","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"}],"container-title":["Vision"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2411-5150\/5\/3\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:25:10Z","timestamp":1760163910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2411-5150\/5\/3\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["vision5030034"],"URL":"https:\/\/doi.org\/10.3390\/vision5030034","relation":{},"ISSN":["2411-5150"],"issn-type":[{"value":"2411-5150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]}}}